drugset

drugset / Trial / NCT03659682

GLP1R in Parkinson's Disease

NCT03659682 ↗

Phase 2 Unknown 120 enrolled Oslo University Hospital

RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of the study is to test the neuroprotective and anti-inflammatory properties of semaglutide in idiopathic Parkinson's disease (PD)

Timeline

Start: 2019-01-02
Primary completion: 2024-12-31
Completion: 2024-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Semaglutide	Peptide	1 mg	Subcutaneous

Indications